April 27, 2024

• 

[THE INVESTOR] Korean pharmaceutical firm Samsung Bioepis said on Oct. 24 its accumulated sales in the European market reached US$389.1 million in the first three quarters.

Samsung Bioepis saw sales of its two biosimilar products -- Benepali and Flixabi -- rise from US$379.8 million in the same period last year. The data was provided by Biogen, which is in charge of Samsung Bioepis’ sales in Europe.

By products, sales of Benepali increased 24 percent on-year to US$123.4 million in the third quarter. Flixabi’s sales grew around fourfold over the cited period to post US$11.4 million.

Benepali is a biosimilar referencing Enbrel developed by US-based Amgen and used for the treatment of rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis.

Flixabi, based on Janssen’s Remicade, is used for the treatment of rheumatoid arthritis, Crohn’s disease and ulcerative colitis.

Samsung Bioepis was established in 2012 as a joint venture between Samsung BioLogics and Biogen.

By Song Seung-hyun and newswires (ssh@heraldcorp.com)